miR-146a in Cardiovascular Diseases and Sepsis: An Additional Burden in the Inflammatory Balance?

Ana B. Arroyo1,* Sonia Águila1,* María P. Fernández-Pérez1 Ascensión M. de los Reyes-García1 Laura Reguilón-Gallego1 Laura Zapata-Martínez1 Vicente Vicente1 Constantino Martínez1,** Rocío González-Conejero1,**

1 Department of Hematology and Medical Oncology, Morales Meseguer University Hospital, Centro Regional de Hemodonación, Universidad de Murcia, IMIB, Murcia, Spain

Address for correspondence Rocío González-Conejero, PhD, Centro Regional de Hemodonación, C/ Ronda de Garay S/N, 30003 Murcia, Spain (e-mail: rocio.gonzalez@carm.es).
Constantino Martínez, PhD, Centro Regional de Hemodonación, C/ Ronda de Garay S/N, 30003 Murcia, Spain (e-mail: constant@um.es).

Abstract

The new concept of thrombosis associated with an inflammatory process is called thromboinflammation. Indeed, both thrombosis and inflammation interplay one with the other in a feed forward manner amplifying the whole process. This pathological reaction in response to a wide variety of sterile or non-sterile stimuli eventually causes acute organ damage. In this context, neutrophils, mainly involved in eliminating pathogens as an early barrier to infection, form neutrophil extracellular traps (NETs) that are antimicrobial structures responsible of deleterious side effects such as thrombotic complications. Although NETosis mechanisms are being unraveled, there are still many regulatory elements that have to be discovered. Micro-ribonucleic acids (miRNAs) are important modulators of gene expression implicated in human pathophysiology almost two decades ago. Among the different miRNAs implicated in inflammation, miR-146a is of special interest because: (1) it regulates among others, Toll-like receptors/nuclear factor-κB axis which is of paramount importance in inflammatory processes, (2) it regulates the formation of NETs by modifying their aging phenotype, and (3) it has expression levels that may decrease among individuals up to 50%, controlled in part by the presence of several polymorphisms. In this article, we will review the main characteristics of miR-146a biology. In addition, we will detail how miR-146a is implicated in the development of two paradigmatic diseases in which thrombosis and inflammation interact, cardiovascular diseases and sepsis, and their association with the presence of miR-146a polymorphisms and the use of miR-146a as a marker of cardiovascular diseases and sepsis.

Keywords
g► polymorphisms
g► miRNA
g► cardiovascular disease

Introduction

Thromboinflammation relies on the interplay between thrombosis and inflammation (through the activation of the hemostatic and coagulation system and the innate and adaptive immunity) and it has been recognized as a pathophysiological process in response to a wide variety of sterile and non-sterile stimuli causing in some cases acute organ damage.1,2 Of special interest in this field are micro-ribonucleic acids (miRNAs), and among them, we here highlight miR-146a. This miRNA has been extensively studied given its prominent regulatory role in inflammatory and immune processes.3,4 Additionally, genetic and epigenetic regulation

© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG,
Rüdigerstraße 14,
70469 Stuttgart, Germany
ISSN 0340-6245.

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
of miR-146a expression in humans provide excellent models to evaluate the role of this miRNA in different pathologies.  

In this review, we will summarize the biology of miR-146a and its function in the interplay between inflammation and thrombosis, especially focusing in cardiovascular diseases (CVDs) and sepsis. These pathologies have been over the years separated in different categories. Interestingly, it has recently been proposed that they both share pathophysiological signaling pathways and common genetic variants. Thus, both diseases share similar endpoints of inflammation, coagulation, and endothelial activation.

**Biosynthesis of miRNAs**

It has been almost two decades since miRNAs were discovered as important regulators of gene expression in disease. miRNA maturation is a complex process that starts in the nucleus where miRNA genes are transcribed by RNA polymerase II, giving rise to a product called pri-miRNA that is further processed into pre-miRNA by the microprocessor catalytic complex, composed by DROSHA and DGR8. The resulting pre-miRNA molecule is a 3′overhang hairpin-like structure of approximately 60 nucleotides. The pre-miRNA is then exported to the cytoplasm by a RanGTP-dependent exportin (XPO5) allowing an additional processing step by DICER resulting in a new approximately 22 nucleotide mature double-strand miRNA. At that point, a single-stranded miRNA is inserted in a functional macromolecular unit, containing among other the argonaute protein 2 (AGO2), recognizing its target messenger RNA (mRNA) by base pairing, containing among other the argonaute protein 2 (AGO2), modulate miR-146a levels.

miR-146a Genetics and Regulation

The gene encoding mature miR-146a (MIR146A) is located on chromosome 5 (5q33.3) in humans and on chromosome 11 (B1.1) in mice. As it happens for the majority of miRNAs, miR-146a is highly conserved in mammalian (www.mirbase.org). The mature sequences were first assigned the name of the mRNA with or without an asterisk, that is, miR-146a (the predominant product) and miR-146a* (from the opposite arm of the precursor), but later (2011) a definitive nomenclature, miR-146a-5p (from the 5′ arm) and miR-146a-3p (from the 3′ arm), was established. In the case of miR-146a, the mature form that has been more extensively studied is miR-146a-5p. Since our studies and the references included in the review refer to this form, we used miR-146a throughout the text. Indeed, only a few studies have analyzed the role of miR-146a-3p and they were not included in the present review. Additionally, letter suffix denotes closely related mature sequences, in the case of miR-146a, there is a close miRNA, miR-146b (located in chromosome 10) that differs from miR-146a by two nucleotides located in the 3′ end, both miRNAs share the same seed region (located in the 5′ end) and most of the targets. The regulation of miR-146a expression is complex and may be performed at different levels as we will describe below. miR-146a transcription is executed by a promoter located 16 kb upstream of MIR146A. Different putative binding sites for a series of transcription factors were characterized in this promoter (Fig. 1A). Taganov et al demonstrated that miR-146a expression was mainly regulated by nuclear factor-kB (NF-kB) through Toll-like receptors (TLRs) such as TLR4 that is activated by lipopolysaccharide (LPS). In addition, other cytokines such as interleukin-1β (IL-1β) or tumor necrosis factor (TNF-α) also increased the levels of mature miR-146a. Another study revealed that the transcription factor ETS-1 could potentially regulate the expression of miR-146a. Indeed, an ETS-1 knockdown model provokes the inability to induce miR-146a expression in vitro. On the opposite side, in vitro models showed that a c-Myc binding site, located in the promoter region, is able to repress the expression of miR-146a. But other regulatory processes also take place at a genetic level. Different single-nucleotide polymorphisms (miR-SNPs) have been described to modulate miR-146a levels. In this review, we will focus on three, rs2431697, rs2910164, and rs57095329, that have been extensively studied (Fig. 1A). The first functional miR-SNP to be characterized was rs57095329 (MAF 0.26 in Asians and 0.025 in Europeans; https://www.ncbi.nlm.nih.gov/snp/). This miR-SNP is located in the miR-146a promoter and the G allele decreases the binding affinity of ETS-1, reducing miR-146a levels by approximately 40%. Another widely studied miR-SNP is rs2910164 (MAF 0.70 in Asians and 0.24 in Europeans; https://www.ncbi.nlm.nih.gov/snp/) that is located in the pre-miR-146a. The minor C allele causes mispairing within the hairpin affecting the efficiency of pri-miR-146a processing and probably the stability and/or efficiency of pre-miR-146a export to the cytoplasm and reducing the levels by more than 40% in CC homozygous. Another study revealed that miR-146a is associated with various diseases where inflammation is an important issue.

miR-146a in Thromboinflammatory Diseases

We will thoroughly develop the effects of miR-146a in inflammation, and suppressed in most of the targets. The regulation of miR-146a expression is complex and may be performed at different levels as we will describe below. miR-146a transcription is executed by a promoter located 16 kb upstream of MIR146A. Different putative binding sites for a series of transcription factors were characterized in this promoter (–Fig. 1A). Taganov et al demonstrated that miR-146a expression was mainly regulated by nuclear factor-kB (NF-kB) through Toll-like receptors (TLRs) such as TLR4 that is activated by lipopolysaccharide (LPS). In addition, other cytokines such as interleukin-1β (IL-1β) or tumor necrosis factor (TNF-α) also increased the levels of mature miR-146a. Another study revealed that the transcription factor ETS-1 could potentially regulate the expression of miR-146a. Indeed, an ETS-1 knockdown model provokes the inability to induce miR-146a expression in vitro. On the opposite side, in vitro models showed that a c-Myc binding site, located in the promoter region, is able to repress the expression of miR-146a. But other regulatory processes also take place at a genetic level. Different single-nucleotide polymorphisms (miR-SNPs) have been described to modulate miR-146a levels. In this review, we will focus on three, rs2431697, rs2910164, and rs57095329, that have been extensively studied (–Fig. 1A). The first functional miR-SNP to be characterized was rs57095329 (MAF 0.26 in Asians and 0.025 in Europeans; https://www.ncbi.nlm.nih.gov/snp/). This miR-SNP is located in the miR-146a promoter and the G allele decreases the binding affinity of ETS-1, reducing miR-146a levels by approximately 40%. Another widely studied miR-SNP is rs2910164 (MAF 0.70 in Asians and 0.24 in Europeans; https://www.ncbi.nlm.nih.gov/snp/) that is located in the pre-miR-146a. The minor C allele causes mispairing within the hairpin affecting the efficiency of pri-miR-146a processing and probably the stability and/or efficiency of pre-miR-146a export to the cytoplasm and reducing the levels by more than 40% in CC homozygous. Another study revealed that miR-146a is associated with various diseases where inflammation is an important issue. Indeed, an ETS-1 knockdown model provokes the inability to induce miR-146a expression in vitro. On the opposite side, in vitro models showed that a c-Myc binding site, located in the promoter region, is able to repress the expression of miR-146a. But other regulatory processes also take place at a genetic level. Different single-nucleotide polymorphisms (miR-SNPs) have been described to modulate miR-146a levels.

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
in endometrial cancer, NIFK antisense RNA 1 (NIFK-AS1) inhibited the M2-like polarization of macrophages reducing the estrogen-induced proliferation, migration, and invasion of cancer cells by reducing miR-146a-5p levels through a sponging mechanism.

**Biological Functions of miR-146a in Immune Cells**

miR-146a is a critical molecular brake of inflammation that regulates among other the TLR4/NF-κB pathway. Indeed, Taganov et al demonstrated in THP-1 cells that miR-146a directly modulates the expression of TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1) that play an essential role in controlling the TLR4/NF-κB pathway\(^\text{15}\) (∆Fig. 2). A few in vitro studies have shown that miR-146a may also regulate the expression of TLR4, but in vivo studies are mandatory to further confirm this important regulation.\(^\text{27-29}\)

As mentioned above, LPS through TLR4/NF-κB promotes the expression of inflammatory cytokines such as IL-6, IL-8, IL-1β, or TNF-α and miR-146a controls overwhelmed cellular response to inflammatory signals through a negative feedback regulatory loop.\(^\text{15,30,31}\) In 2011, Baltimore’s laboratory published two studies using a deficient mouse model for miR-146a that gave many clues on the pathological role of miR-146a.\(^\text{30,32}\) These mice react to LPS challenge with an important inflammatory response displaying high levels of IL-6 in serum, among other. Interestingly, aging also provokes them an increased inflammatory status. Indeed, the authors showed that aged miR-146a\(^{-/-}\) mice developed a myeloproliferative phenotype and tumors in their secondary lymphoid organs.\(^\text{30}\) These data suggest a role for miR-146a far beyond the
miR-146a deiciency increases NETosis.41

In addition, miR-146a has a key role in macrophages polarization and tolerance, relevant processes in atherosclerosis development.42 Importantly, miR-146a deficiency promoted M1 phenotype and its overexpression resulted in M2 macrophages by decreasing the expression of NOTCH receptor 1 (NOTCH1) an important regulator of macrophage differentiation and activation (Fig. 3).43,44 This miRNA also inhibited the differentiation to M1 of hepatic macrophages by targeting signal transducer and activator of transcription 1 (STAT1) and consequently the interferon-γ signaling.45

Oxidized low-density lipoprotein (oxLDL), an important inducer of atherosclerosis, may also regulate miR-146a expression. OxLDL-stimulated macrophages presented a

![Fig. 2 Regulation of the Toll-like receptor (TLR) 4/nuclear factor-kB (NF-kB) axis by miR-146a. Binding of lipopolysaccharide (LPS) to TLR4 leads to the activation of NF-kB and its translocation to the nucleus. NF-kB induces the transcription of several proinflammatory genes (such as interleukin [IL]-6) and also promotes the transcription of pri-miR-146a that after a series of maturation processes gives rise to the mature miR-146a that will act through a negative feedback regulatory loop to essentially control the levels of TLR4 and IRAK1, main players of the TLR4/NF-kB axis.](image)

One of the crucial elements implicated in thrombosis-linked inflammation is the neutrophil. These cells are mainly involved in eliminating pathogens and being an early barrier to infection.35 In 2004, Brinkmann et al, in a landmark study, characterized a new mechanism, later termed NETosis, by which neutrophils are able to remove bacteria under certain stresses such as infection.36 NETs are structures composed of nuclear chromatin and associated with nuclear histones as well as cytoplasmic and granular antimicrobial proteins.37 Their association with CVs, venous thrombosis, and autoimmune diseases has been largely documented.38–40 We recently showed that miR-146a was involved in NET formation using a miR-146a−/− mouse model. Our results demonstrated that miR-146a deiciency promotes in vitro the intrinsic capacity of neutrophils to form NETs in response to phorbol 12-myristate 13-acetate.40 On the other hand, sterile stresses such as atherosclerosis and non-sterile such as endotoxemia produced an increased in NETosis in miR-146a−/− mice versus wild-type (WT).40 Although the precise mechanism is unknown, the lack of miR-146a provoked changes in neutrophils that display an aging phenotype characterized by the markers CD62Llow CD11bhigh Cxcr4high, and an overexpression of Tlr4 in the aged population.41 miR-146a−/− neutrophils also showed a lower expression of Cxcr1, that has been associated with a proinflammatory phenotype. All these features together with an increased formation of reactive oxygen species observed in miR-146a−/− mice, by a yet to discover mechanism, may explain in part why miR-146a deficiency increases NETosis.41

miR-146a expression. OxLDL-stimulated macrophages presented a
downregulation of miR-146a through lectin-type oxLDL receptor 1 (LOX-1). In contrast, miR-146a overexpression provoked a reduction in TLR4 expression and higher cholesterol content in macrophages. miR-146a may inhibit lipid uptake by blockade of TLR4–Src–FAK–JNK axis and the phosphorylation of protein tyrosine kinase 2 (Pyk2) and paxillin, a signal transduction adaptor protein. Accordingly, the expression of IL-6, IL-8, monocyte chemotactic protein-1, and matrix metalloproteinase 9 decreased via miR-146a via TLR4-TRAF6/IRAK1-AKT. Indeed, the direct repression of TLR4 by miR-146a has been extensively characterized in different pathologies such as diabetic retinopathy, inflammation derived of endotoxin, and ischemia/reperfusion (I/R) injury.

### Relevance of miR-146a in the Pathophysiology Underlying Thromboinflammatory Diseases

**Atherosclerosis**

Atherosclerosis is the main underlying process driving to most cardiovascular pathologies including coronary artery disease (CAD), ischemic stroke (IS), or acute myocardial infarction (AMI). Progressing atherosclerotic plaques may eventually rupture, thereby inducing intraluminal thrombosis leading to adverse cardiac events. Since inflammation is a key contributor to all stages of atherosclerosis and its fatal cardiovascular consequences, miR-146a was assumed to be a promising anti-inflammatory and atheroprotective agent. Nonetheless, apolipoprotein E (ApoE) controls in atherosclerosis appears complex, and it is important to therapeutically focus on a specific cell type at a particular stage of atherogenesis. Importantly, various association studies have indicated that MIR146A miR-SNPs (rs2431697 and rs2910164) play a role in atherosclerosis-related diseases (i.e., CAD and IS) development and progression. These studies have been performed in different populations and genetic make-up. Our group has performed a meta-analysis that the T variant of rs2431697 (associated with low miR-146a levels) was predictor of adverse cardiovascular events, such as IS, in a cohort of 901 AF patients. Subsequently, we evidenced that the TT genotype was associated with high inflammatory status and NET release, which could explain its prothrombotic effect. In agreement with our findings, Wang et al found that rs2431697 T carriers had an increased CAD risk in a Chinese population.

In contrast, the relationship between rs2910164 and CVD has been widely studied although the results are still inconclusive. Zhong et al revealed that rs2910164 was associated with an increased risk of atherosclerotic cerebral infarction (ACI) in a Chinese cohort. Patients with reduced miR-146a expression in PBMCs exhibited an increased risk of ACI. Two additional studies evaluated the effect of rs2910164, finding that the G allele was associated with an increased risk of stroke or CAD. Ramkaran et al described higher levels of miR-146a in PBMCs from young CAD patient carrying rs2910164 CC genotype. These patients displayed significantly lower levels of IRAK1 and TRAF6, together with low
levels of NF-κB and C-reactive protein. Their observations implicated a protective function of CC genotype by increasing miR-146a levels and reducing inflammation in CAD patients.67 However, other researchers have shown that the G allele of rs2910164 decreased the risk of CAD by downregulating the expression of miR-146a.53,68,69 Hence, the inconsistency between results of several publications could be attributed to different ethnic groups and study designs. It is important to note that most of the studies were performed in Chinese populations and data gaps are evident in the Caucasian population. Clearly, further studies, including different geographical domains and larger sample sizes, are needed to globally understand the role of these miR-SNPs in CVD.

Myocardial Infarction
Several evidences directly link miR-146a and MI pathology. Notably, an altered expression of miR-146a has been found in autopsied heart tissue from MI patients compared with control hearts.70 Indeed, MI patients with complications including ventricular rupture (VR) had upregulated tissue miR-146a levels versus those without VR.70 The authors suggested that miR-146a increased in response to an intense inflammatory reaction that leads to the pathogenesis of VR after MI.70 In addition, the role of miR-146a in heart diseases has been widely studied in animal models. However, it has not yet been determined whether its role is protective or harmful to the heart since miR-146a function varies depending on the heart disease model used. Wang et al71 reported that miR-146a transfection into mouse hearts protected against myocardial I/R injury. miR-146a significantly decreased myocardial infarct size and attenuated myocardial apoptosis through the attenuation of NF-κB activation and inflammatory cytokine production by suppressing IraK1 and Traf6 expression.71 Similarly, another recent study found that the injection of miR-146a-transfected human mesenchymal stem cells (hMSC-miR-146a) after myocardial I/R injury improved cardiac function in rats by reducing the fibrotic area through the secretion of vascular endothelial growth factor.72 A new finding indicated that exosomes derived from miR-146a-modified adipose stem cells play a key role in cardioprotection after MI by suppressing MI-induced apoptosis, inflammatory response, and fibrosis in an MI rat model.73 Moreover, both in vivo and in vitro experiments found that miR-146a directly targeted early growth response factor 1, a well-known inducer of myocardial damage, and reverse MI or hypoxia-induced TLR4-NF-κB signal activation.73 Another study in miR-146a−/− mice revealed that miR-146a deficiency increased infarct size and apoptosis after I/R injury through the upregulation of 19 apoptosis-related genes such as mediator complex subunit 1 (Med1).74 On the other hand, tyrosine kinases inhibitors agents such as sunitinib (SNT), beyond their beneficial effects on cancer, have shown adverse effects on the cardiovascular system.75 Interestingly, Shen et al showed a significant downregulation of miR-146a in the myocardium of SNT-treated mice.75 Indeed, they demonstrated the protective effect of miR-146a upregulation on SNT-induced cardiac contractile dysfunction in vivo and in vitro by targeting cardiac phospholamban and ankyrin-2, both strongly involved in cardiac contractility.75 Lastly, interesting data suggested that combination of miR-21 and miR-146a injection in mice (both with cytoprotective roles) had a greater protective effect against cardiac I/R-induced apoptosis compared with their individual effect.76 Thus, Huang et al showed that this synergistic action was mediated by enhanced inhibition of apoptosis of cardiomyocytes by the miR-21/PTEN-AKT/p-p38 caspase-3 and miR-146a/TRA6F/p-p38 caspase-3 signal pathways.76 Nevertheless, despite most studies attribute to miR-146a a cardioprotective role, others oppose them.77–79 Particularly, it is worth mentioning the study by Oh et al that tested the effects of miR-146a modulation in transverse aortic constriction-induced heart failure (HF) models. They demonstrated that overexpression of miR-146a attenuated cardiac contractile function by direct inhibition of the small ubiquitin-like modifier 1 (Sumo1) and the sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) expression, both previously associated with HF protection.

Therefore, further investigation is needed to clearly define the role of miR-146a during HF in particular and CVD in general, and to better define the cell-specific function of miR-146a under different pathological stresses.

Sepsis
Sepsis is the paradigm for inflammatory systemic diseases associated with high morbidity and mortality in intensive care units.80 Innate and adaptive immune systems’ dysfunctions participate as drivers of this pathology in a network not fully known. Since activation of the coagulation cascade occurs in most patients with sepsis, the interplay between inflammation and coagulation has a crucial role in its pathophysiology.81 Within hours after its initiation, the severe systemic inflammatory response shifts to an adaptive anti-inflammatory state caused in part by endotoxin tolerance that plays a key role in sepsis by limiting the negative consequences of an excessive inflammation and the endotoxin shock.82 Several studies strongly support a crucial role for miR-146a in endotoxin tolerance by acting as a fine-tuning mechanism to prevent an overstimulation of the inflammatory response to persistent bacteria exposures.47,83–86 In vitro experiments using human monocyteic cells reported that miR-146a levels increased following LPS treatment (through TLR4) and negatively correlated with inflammatory cytokines as cells develop a status of LPS tolerance.31 Importantly, tolerance induction required miR-146a upregulation and transfection of exogenous miR-146a prompted endotoxin tolerance, even in the absence of LPS priming.33 Subsequent works confirmed these findings and showed that miR-146a was necessary for LPS-induced cross-tolerance to different TLR ligands.31,87,88 Interestingly, miR-146a protection in endotoxin tolerance was also observed in morphine treatment, the main analgesic used in postoperative pain management, and a prevalent recreational drug with well-known adverse effects on the immune system.85 Chronic morphine treatment mitigated endotoxin tolerance, resulting in persistent inflammation, sepsisemia, and septic shock by
downregulating LPS-induced miR-146a in macrophages. Complementary studies by using various animal models have confirmed the critical role of miR-146a in the control of inflammation and organ dysfunction during bacteria or endotoxin-induced sepsis, involving macrophages as a major mechanism of innate immunity defense. In 2019, Funahashi et al demonstrated that miR-146a induction in splenic macrophages led to the attenuation of excessive inflammation, mortality rate, and severity of organ injury from polymicrobial sepsis induced by cecal ligation puncture (CLP) in mice. Another recent work reported the protective role of miR-146a in LPS-induced organ damage and in the inflammatory response in mice by inhibiting the Notch1 signal in macrophages. This finding suggested miR-146a-Notch1-NF-κB axis as a potential target for the treatment and prevention of sepsis. Concordantly, miR-146a−/− mice succumbed earlier than WT to septic shock induced by LPS. Pan et al provided evidence supporting Jumonji domain-containing protein D3 (JMJD3), an histone lysine demethylase, as an epigenetic regulator of miR-146a transcription in an Escherichia coli-induced sepsis model. The authors showed that inhibition of JMJD3, upregulated miR-146a transcription in peritoneal macrophages, protecting mice against early septic death. Alternatively, Song et al found in a CLP-induced sepsis that miR-146a upregulated by IL-1β was selectively packaged into exosomes, transferred to recipient macrophages, where it regulated M1-M2 transition, and finally led to reduced inflammation and increased survival in septic mice.

miR-146a dysregulation has also been described in sepsis in humans. With an interesting approach, Braza-Boils et al have described that miR-146a was significantly downregulated in plasma after LPS treatment in an experimental human model of low-dose endotoxemia in volunteers. These results suggest that LPS alone could also be inducing changes in miR-146a expression in humans. Furthermore, miR-146a dysregulation has also been associated with clinical manifestations of sepsis. The downregulation of miR-146a in PBMCs from septic patients have been correlated with elevated IL-6 and monocyte proliferation. Indeed, IL-6 levels directly correlated with Sequential Organ Failure Assessment score in these patients. In addition, a couple of reports showed indirect associations between miR-146a miR-SNPs, its targets and sepsis. Shao et al found for the first time a significant association between rs2910164 genotype (but not with rs57095329), miR-146a levels, and the susceptibility for sepsis, although they could not demonstrate that miR-146a targets were regulated by this miR-SNP. Probably, clinical heterogeneity of these patients and their treatments masked the relation between miR-146a targets and the inflammatory status of septic patients. Meanwhile, Han et al, reported that rs2910164 genotype conferred a worse outcome in those patients.

On the other hand, cardiovascular complications are major consequences of sepsis/septic shock and are closely associated with increased morbimortality. Hence, Gao et al demonstrated that overexpression of miR-146a into mice myocardium subjected to CLP-induced sepsis protected them against cardiac dysfunction by markedly reducing the infiltration of macrophages and neutrophils into the myocardium and attenuating inflammatory response in both cardiomyocytes and macrophages via suppression of NF-κB activity through Irak1 and Trafl downregulation. Moreover, a subsequent in vitro study reported that the overexpression of miR-146a mitigated the damage of cardiomyocytes induced by LPS in heart-derived H9C2 myocardial cells through negatively regulating NF-κB activation and inflammatory cytokine production via targeting the type I receptor protein tyrosine Erbb4. In addition, Xie et al reported that miR-146a, through regulating Tlr-4/NF-κB signaling pathway, improved inflammation and decreased myocardial injury markers in rats treated with LPS. Thus, all these findings support that miR-146a could be a useful agent for protection against sepsis-induced cardiac dysfunction. In fact, we have demonstrated an association between miR-146a rs2431697 genotype and risk for cardiovascular events in CAP patients. Thus, among 30 hospitalized patients with cardiovascular events, 29 carried the T allele (relative risk = 9.61, 95% confidence interval 1.28–72.15). Increased cardiovascular risk remained significant for T carriers 30 days after hospitalization. Interestingly, our results pointed to NETosis as a functional way by which miR-146a levels lead to thrombosis in sepsis. Thus, among patients with the highest plasma levels of deoxyribonucleic acid/citrullinated histone H3 (citH3), those bearing T allele were threefold more frequent than CC. Furthermore, miR146a−/− mice injected with LPS presented higher citH3 and thrombin-antithrombin complex levels in plasma than WT and more severe lung injury. Based on these results miR-146a might have a role in immunothrombosis in septic patients. The relationship between miR-146a levels and NETosis in sepsis evolution is an interesting field that we are exploring.

miR-146a as a Plasma Marker
Cardiovascular Diseases
After the discovery of miRNA stability in body fluids in 2008, a plethora of studies have evidenced the presence of a variety of circulating cell-free miRNAs. The ability of these miRNAs to reflect physiological and pathophysiological conditions as well as their high stability in stored patient samples underlines the potential of these molecules to serve as biomarkers for several diseases. Here, we focus on the potential of circulating miR-146a as a biomarker in thromboinflammatory disorders.

In accord with the protective role of miR-146a in atherosclerosis, Wagner et al reported that plasma levels of miR-146a were slightly downregulated in high-density lipoprotein (HDL) fraction from acute coronary syndrome (ACS) patients compared with healthy subjects. However, this study has two major limitations: (1) the small sample size (10/group) and (2) that HDL-bound miR-146a fraction was less than 1% and did not correlate with total plasma levels of miR-146a. On the contrary, Oerlemans et al reported that serum miR-146a levels were significantly increased in those patients who developed an ACS, including those with negative high-sensitive cardiac troponin T (hs-cTnT) or < 3 hours of onset of chest pain. In
addition, circulating miR-146a levels discriminate non-ST elevation MI versus unstable angina. These results were supported by a study showing that serum miR-146a levels were upregulated in CAD patients compared with controls. In this study, although there were no differences in miR-146a levels between patients with stable versus unstable angina, miR-146a levels were significantly higher in MI versus stable angina patients. Interestingly, this study also showed that miR-146a was mainly associated with serum HDL.

In the same direction, Quan et al found a positive correlation between plasma miR-146a levels and the severity of coronary heart disease (CHD) measured by Gensini score. Interestingly, among CHD patients, those with subclinical hypothyroidism (SCH) exhibited the highest plasma miR-146a levels that positively correlated with thyroid-stimulating hormone levels, thus highlighting a potential predictive value of plasma miR-146a for CHD among individuals with SCH. But the most enlightening study showed that plasma miR-146a levels were increased in MI patients compared with control subjects both, before and after percutaneous coronary intervention (PCI), showing a decrease of miR-146a levels after PCI. They also found a significant positive correlation of miR-146a with other biomarkers such as N-terminal pro-brain natriuretic peptide and Hs-cTNT both, before and after PCI. Interestingly, it has been proposed that miRNAs can be released into plasma during plaque rupture, thrombus formation, and myocardial I/R injury (necrosis and apoptosis), thus mirroring the levels found in the artery walls of origin. Whether the increase in plasma miR-146a levels found in CAD/CHD/AMI patients in those studies may reflect a miR-146a-driven pathogenic or, on the contrary, a compensatory mechanism, has yet to be elucidated.

The alteration in circulating miR-146a levels has also been reported in other cardiovascular clinical entities. Halkein et al showed that levels of exosomal miR-146a were significantly higher in plasma from patients with acute peripartum/postpartum cardiomyopathy than in healthy postpartum controls and patients with dilated cardiomyopathy. Kim et al examined tissue and plasma miRNAs specifically associated with atherosclerotic abdominal aortic aneurysm (AAA), and found that miR-146a was significantly upregulated in AAA tissue compared with normal aortic wall tissue, while it was significantly downregulated in the plasma of AAA patients compared with the plasma from healthy controls.

Sepsis

Several studies have remarked the role of miR-146a as a promising prognostic and diagnostic biomarker for sepsis. Wang et al reported that serum level of miR-146a was significantly reduced in patients suffering from sepsis compared with nonseptic systemic inflammatory response syndrome (SIRS) patients and healthy individuals, suggesting that miR-146a could distinguish sepsis from SIRS caused by other noninfectious diseases. Subsequently, results from another study also showed higher serum miR-146a levels in nonsepsis SIRS patients compared with sepsis patients, suggesting that miR-146a may be an optimal diagnostic tool for sepsis. Caserta et al confirmed the decrease of miR-146a in sepsis compared with noninfective SIRS. Recently, Chen et al showed that high levels of miR-146a were associated with higher sepsis risk, disease severity, and systemic inflammation.

Conclusion and Future Perspectives

Interaction between thrombosis and inflammation is a central feature of several highly prevalent pathologies. Thus, it is essential to understand the mechanisms and to discover new elements leading to thromboinflammatory processes. This is a key to develop new and effective therapeutic tools to fight thrombosis in several diseases. In this context, current evidences strongly support that miR-146a plays a relevant role in arterial thrombosis in diseases with an important inflammatory background. miR-146a is ubiquitously expressed and it exerts several effects in different cell types ranging from endothelial cells and macrophages in atherosclerosis to leukocytes in autoimmune diseases. Whether miR-146a affect other cells such as macrophages or platelets or processes that may affect NETosis have to be further searched. In addition, the discovery of new miR-146a targets with a role in thrombosis and inflammation may be determinant and approaches using genomics and transcriptomics in the adequate samples from the adequate patients or animal model may help in this endeavor. In this sense, another vital point is to know if miR-SNPs affecting miR-146a levels also produce neutrophil phenotypic changes as those observed in mice and would explain the association between the presence of these genetic alterations and thrombosis in patients with thromboinflammatory diseases such as those described in the present review.

Another interesting aspect is the use of miR-146a as a biomarker of a thromboinflammatory condition. In this case, there is still work to do concerning the standardization of protocols, and this is extensive to any miRNA. There are many limitations in the studies related with the use of miRNAs as markers of diseases and the best way of extraction and quantification from plasma, serum, other fluids, or EVs. Inconsistencies and variations in results between studies can mostly be attributed to preanalytical variation arising from different protocols as well as different normalization strategies. The use of plasma or serum, the purification technique, batch effects, the anticoagulant used, leukocyte and platelet contamination, hemolysis, sample storage time, and quantification technique are important factors that influence miRNA plasma level variability observed between studies. In addition, to obtain enough statistical power, cohorts have to be well calculated to obtain consistent and reproducible results. How and when the samples are obtained also accounts for the large variability observed between studies. For example, drug treatment in CVD or in sepsis can modify miRNA expression levels and may confound the results as shown in several works from Mayr’s laboratory among others. Thus, given the potential
miR-146a plays a relevant role in thromboinflammation in sterile and nonsterile conditions. The presence of miR-single-nucleotide polymorphisms (SNPs) such as rs2431697 and rs2910164 promote a phenotype with low levels of miR-146a. Upon sterile or nonsterile stimuli, neutrophils expressing the minor alleles would be more prone to NETosis leading to a higher thromboinflammatory process.

**Table 1** List of genes targeted by miR-146a

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Functions</th>
<th>Reference(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRAK1</td>
<td>Essential role in controlling the TLR4/NF-kB pathway</td>
<td>15</td>
</tr>
<tr>
<td>IRAK2</td>
<td>Component of the IL-1R signaling complex, promotes NF-kB signaling</td>
<td>123</td>
</tr>
<tr>
<td>TRAF6</td>
<td>Promotes NF-kB signaling</td>
<td>15</td>
</tr>
<tr>
<td>TLR4</td>
<td>Production of inflammatory cytokines via NF-kB</td>
<td>28</td>
</tr>
<tr>
<td>STAT1</td>
<td>Crucial role in IFN-γ signaling</td>
<td>45</td>
</tr>
<tr>
<td>NOTCH1</td>
<td>Regulator of macrophage differentiation and activation</td>
<td>43</td>
</tr>
<tr>
<td>NOTCH2</td>
<td>Development of marginal zone B cells</td>
<td>124</td>
</tr>
<tr>
<td>CXCR4</td>
<td>Chemokine receptor, involved in calcium mobilization, integrin-mediated adhesion, gene transcription, and proliferation</td>
<td>125</td>
</tr>
<tr>
<td>NUMB</td>
<td>Negatively regulated NOTCH signaling</td>
<td>124</td>
</tr>
<tr>
<td>SOD2</td>
<td>Radical scavenger, essential for balancing the intracellular ROS</td>
<td>126</td>
</tr>
<tr>
<td>EGR1</td>
<td>Promotes TLR4-NF-kB signal activation induced by hypoxia</td>
<td>73</td>
</tr>
<tr>
<td>CARD10</td>
<td>Specifically required for GPCR-induced NF-κB activation</td>
<td>127</td>
</tr>
<tr>
<td>COPS8</td>
<td>Controls NF-kB activation in activated T cells</td>
<td>127</td>
</tr>
<tr>
<td>IL-6, IL-8, CCL5</td>
<td>Chemokines for acute inflammatory responses</td>
<td>128</td>
</tr>
<tr>
<td>COX2</td>
<td>Prostanoid biosynthesis, involved in many age-related diseases</td>
<td>129</td>
</tr>
</tbody>
</table>

Abbreviations: GPCR, G-protein-coupled receptor; IFN-γ: interferon γ; IA, інтерлейкін; NF-κB, nuclear factor-kB; TLR, Toll-like receptor.
of this technique to diagnose or predict CVD an effort in standardization is necessary to accelerate its use in the future. However, there are already some miRNA panels that are commercially available for the diagnosis of certain pathologies and additional effort must be done to include new applications.121

The use of miR-146a as a therapeutic tool is also an exciting future application. Several studies in animal models have shown that miR-146a replacement therapy favors an anti-inflammatory status that could be beneficial in thromboinflammatory diseases such as CVD,122 yet no clinical trials have started with miR-146a. Indeed, miRNA therapeutics employing miRNA mimics or antagonims are currently under clinical trials in different diseases such as cancer, hepatitis C, or HF.122 Thus, additional studies on potential off-target effects and efficient delivery methods are needed to allow envisioning miR-146a as an effective therapeutic drug against thromboinflammatory diseases.

Funding
This work was supported by research grants from Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional “Investing in your future” (P11/00051) (PFIS18/0045: A.M. de los Reyes-García) (CD18/00044: S. Águila) (CM19/00037: L. Reguilon-Gallego), and Fundación Séneca (19873/GERM/15).

Conflict of Interest
None declared.

Acknowledgments
The authors would like to acknowledge Servier Medical Art (https://smart.servier.com/; Laboratoires Servier, France) for providing templates that were used for creating figures.

References
1 Guo L, Rondina MT. The era of thromboinflammation: platelets are dynamic sensors and effector cells during infectious diseases. Front Immunol 2019;10:2204
5 Zhang Z, Zhang Y, Sun XX, Ma X, Chen ZN. microRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol Cancer 2015; 14:5
10 Ayoub KF, Pothineni NVK, Rutland J, Ding Z, Mehta JL. Immunity, inflammation, and oxidative stress in heart failure: emerging molecular targets. Cardiovasc Drugs Ther 2017;31(5-6):593–608
25 Sun W, Ma M, Yu H, Yu H. Inhibition of IncRNA X activate specific transcript ameliorates inflammatory pain by suppressing satellite glial cell activation and inflammation by acting as a sponge of miR-146a to inhibit Na+, l7. J Cell Biochem 2018;119 (12):9888–9898
miR-146a in Thromboinflammatory Diseases  


29 Ye EA, Steine JEE Ymir-146a attenuates inflammatory pathways mediated by TLR4/NF-κB and TNFα to protect primary human retinal microvascular endothelial cells grown in high glucose. Mediators Inflamm 2016;2016:3958453


33 Ferrer-Marin F, Arroyo AB, Bellosillo B, et al; GEMFIN Group. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. Leukemia 2020;34(10):2648–2659

34 Zhao JL, Rao DS, O’Connell RM, Garcia-Flores Y, Baltimore D. MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice. elife 2013;2:e00537


41 Arroyo AB, Fernández-Pérez P, Del Monte A, et al. miR-146a is a pivotal regulator of neutrophil extracellular trap formation promoting thrombosis. Haematologica 2020;haematol.2019.240226


52 Li K, Ching D, Luk FS, Raffai RL. Apolipoprotein E enhances microRNA-146a in monocytes and macrophages to suppress nuclear factor-κB-driven inflammation and atherosclerosis. Circ Res 2013;117(01):e1–e1


66 Ramkaran P, Khan S, Phulukdaree A, Moodley D, Chuturgoon AA. miR-146a polymorphism influences levels of miR-146a, IRAK-1, and TRAF-6 in young patients with coronary artery disease. Cell Biochem Biophys 2014;68(02):259–266


Cornett AL, Lutz CS. Regulation of COX-2 expression by miR-146a in lung cancer cells. RNA 2014;20(09):1419–1430